<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004792.pub5" GROUP_ID="LIVER" ID="869103101510021907" MERGED_FROM="" MODIFIED="2015-06-08 14:37:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="02" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2015-06-08 15:33:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-03-26 11:58:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases</TITLE>
<CONTACT>
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-06-08 15:33:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" MODIFIED="2015-06-08 15:28:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12177" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Ivan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solà</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>isola@santpau.cat</EMAIL_1>
<EMAIL_2>ensayos@cochrane.es</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1>Sant Antoni Maria Claret 171 - Edifici Casa de Convalescència</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalunya</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 932 919 527</PHONE_1>
<PHONE_2/>
<FAX_1>+34 932 919 525</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-06-08 13:46:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="17" MONTH="3" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="2" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="12" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-03-26 11:58:37 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-03-26 11:58:24 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="17" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>No change in conclusion. Randomised clinical trials are still lacking.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-03-26 11:58:37 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="25" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>Searches performed in February 2015; however, there were still no trials on the subject of our review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-03-26 11:55:47 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2015-03-26 14:17:31 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-03-26 14:17:31 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-06-19 04:24:24 +0200" MODIFIED_BY="[Empty name]">
<NAME>Centro Cochrane Iberoamericano</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-03-26 14:17:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Hepato Biliary</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Academic.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-06-08 15:32:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2015-06-08 15:32:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-05-18 17:25:09 +0200" MODIFIED_BY="[Empty name]">Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases</TITLE>
<SUMMARY_BODY MODIFIED="2015-06-08 15:32:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Review question</B>
<BR/>We reviewed vitamin K for upper gastrointestinal bleeding in people with acute liver disease (that is, loss of normal liver functions which occurs in days or weeks; most often, people do not have a pre-existing liver disease) or chronic liver disease (that is, progressive destruction of normal liver functions, usually associated with fibrotic regeneration of the liver tissue).</P>
<P>
<B>Background</B>
<BR/>Upper gastrointestinal bleeding (vomiting of blood) is one of the most frequent causes of morbidity and mortality in the course of liver disease. Vitamin K administration is used as a supplementary intervention, but it is unknown whether it benefits or harms people with acute or chronic liver disease and upper gastrointestinal bleeding.</P>
<P>
<B>Study characteristics</B>
<BR/>We searched scientific databases for studies assessing the benefits and harms of vitamin K in people of any age with liver disease. This updated review found no randomised clinical trials (clinical studies where people are randomly put into one of two or more treatment groups) on the benefits or harms of vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases. The evidence is current to February 2015.</P>
<P>
<B>Key results</B>
<BR/>There is no evidence to recommend or refute the use of vitamin K for upper gastrointestinal bleeding in people with liver diseases.</P>
<P>
<B>Quality of evidence</B>
<BR/>We found no randomised clinical trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-06-08 13:47:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2015-06-08 13:47:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Upper gastrointestinal bleeding is one of the most frequent causes of morbidity and mortality in the course of liver cirrhosis. Several treatments are used for upper gastrointestinal bleeding in people with liver diseases. One of them is vitamin K administration, but it is not known whether it benefits or harms people with acute or chronic liver disease and upper gastrointestinal bleeding. This is an update of this Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-03-26 12:09:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of vitamin K for people with acute or chronic liver disease and upper gastrointestinal bleeding.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-06-08 13:47:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched The Cochrane Hepato-Biliary Controlled Trials Register (February 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2 of 12, 2015), MEDLINE (Ovid SP) (1946 to February 2015), EMBASE (Ovid SP) (1974 to February 2015), Science Citation Index EXPANDED (1900 to February 2015), and LILACS (1982 to 25 February 2015). We sought additional randomised trials from two registries of clinical trials: the World Health Organization Clinical Trials Search Portal and the metaRegister of Controlled Trials. We looked through the reference lists of the retrieved publications and review articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-06-08 13:47:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials irrespective of blinding, language, or publication status for assessment of benefits and harms. We considered observational studies for assessment of harms only.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-06-08 13:47:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>\We aimed to summarise data from randomised clinical trials using Standard Cochrane methodology and assess them according to the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-06-08 13:47:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no randomised trials on vitamin K for upper gastrointestinal bleeding in people with liver diseases assessing benefits and harms of the intervention. We identified no quasi-randomised studies, historically controlled studies, or observational studies assessing harms.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-06-08 13:47:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This updated review found no randomised clinical trials of vitamin K for upper gastrointestinal bleeding in people with liver diseases. The benefits and harms of vitamin K need to be tested in randomised clinical trials. Until randomised clinical trials are conducted to assess the trade-off between benefits and harms, we cannot recommend or refute the use of vitamin K for upper gastrointestinal bleeding in people with liver diseases.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-06-08 13:49:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2015-06-08 13:47:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2015-06-08 13:47:42 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Upper gastrointestinal bleeding is the loss of blood caused by illnesses that affect the alimentary canal from the mouth to the duodenum. According to the volume and speed of blood loss, upper gastrointestinal bleeding can lead to chronic anaemia or acute, life-threatening symptoms. Haematemesis (vomiting of blood) and melena (dark coloured, tarry stools containing digested blood) are the most common symptoms and signs of upper gastrointestinal bleeding (<LINK REF="REF-Green-2003" TYPE="REFERENCE">Green 2003</LINK>). The annual incidence of upper gastrointestinal bleeding in France was 143 people per 100,000 (<LINK REF="REF-Czernichow-2000" TYPE="REFERENCE">Czernichow 2000</LINK>). The annual incidence of acute upper gastrointestinal bleeding in the UK was between 47 and 116 people per 100,000 (<LINK REF="REF-Dallal-2001" TYPE="REFERENCE">Dallal 2001</LINK>). In the United States, from 1998 to 2006, the number of hospitalisations for upper gastrointestinal bleeding per 100,000 people decreased by 14% (<LINK REF="REF-Zhao-2008" TYPE="REFERENCE">Zhao 2008</LINK>). Epidemiology and demographics of upper gastrointestinal bleeding (i.e., prevalence, incidence, and mortality) have been reviewed (<LINK REF="REF-Sostres-2011" TYPE="REFERENCE">Sostres 2011</LINK>).</P>
<P>Upper gastrointestinal bleeding is one of the most frequent causes of morbidity and mortality in the course of liver cirrhosis (<LINK REF="REF-Protell-1981" TYPE="REFERENCE">Protell 1981</LINK>; <LINK REF="REF-Longstreth-1998" TYPE="REFERENCE">Longstreth 1998</LINK>; <LINK REF="REF-del-Olmo-2000" TYPE="REFERENCE">del Olmo 2000</LINK>; <LINK REF="REF-Zaltman-2002" TYPE="REFERENCE">Zaltman 2002</LINK>). In people with advanced cirrhosis, acute upper gastrointestinal bleeding is the most serious and life-threatening complication (<LINK REF="REF-Afessa-2000" TYPE="REFERENCE">Afessa 2000</LINK>; <LINK REF="REF-van-Leerdam-2008" TYPE="REFERENCE">van Leerdam 2008</LINK>). The causes of acute upper gastrointestinal bleeding in people with cirrhosis are: 1. rupture of varices in the oesophagus, stomach, or duodenum; 2. reflux oesophagitis; 3. acute lesions in the mucosal lining of the stomach membrane lesion; 4. peptic ulceration; and 5. reduction in blood coagulation factors (<LINK REF="REF-Amitrano-2002" TYPE="REFERENCE">Amitrano 2002</LINK>; <LINK REF="REF-Green-2003" TYPE="REFERENCE">Green 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-06-08 13:47:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Several primary treatments are used for upper gastrointestinal bleeding in people with liver diseases. These are directed against the source of bleeding, for example, vasoactive treatment or endoscopic therapy for bleeding varices (<LINK REF="REF-Ioannou-1999" TYPE="REFERENCE">Ioannou 1999</LINK>; <LINK REF="REF-D_x0027_Amico-2002" TYPE="REFERENCE">D'Amico 2002</LINK>). Supplementary interventions are also often used including administration of vitamin K, which participates in the control of the formation of coagulation factors II, VII, IX, and X and anticoagulant proteins C and S by the liver. In liver disease, there is impaired synthesis of these clotting factors, resulting in a prolonged prothrombin time (<LINK REF="REF-Blonski-2007" TYPE="REFERENCE">Blonski 2007</LINK>; <LINK REF="REF-Pluta-2010" TYPE="REFERENCE">Pluta 2010</LINK>; <LINK REF="REF-Kavanagh-2011" TYPE="REFERENCE">Kavanagh 2011</LINK>; <LINK REF="REF-Tripodi-2011" TYPE="REFERENCE">Tripodi 2011</LINK>; <LINK REF="REF-Wicklund-2011" TYPE="REFERENCE">Wicklund 2011</LINK>). This lack of production of clotting factors is more likely to be associated with impaired hepatocyte function than with a deficiency in vitamin K. One study, designed to research thrombin generation for assessment of the function of blood coagulation in people with cirrhosis, showed that although the prothrombin time is prolonged in people with cirrhosis, this may not correspond to an actual coagulation impairment (<LINK REF="REF-Tripodi-2005" TYPE="REFERENCE">Tripodi 2005</LINK>). The proposed explanation is that, in liver disease, the reduction of procoagulant factors in people with cirrhosis is compensated for by the reduction of anticoagulant factors, thus leaving the coagulation balance unaltered (<LINK REF="REF-Tripodi-2005" TYPE="REFERENCE">Tripodi 2005</LINK>). Therefore, administration of vitamin K to people with liver disease may have only partial or no effect in improving prolonged prothrombin time.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-06-08 13:47:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>While vitamin K is used for treating coagulopathies in people with upper gastrointestinal bleeding, there appears to be no specific studies supporting its use (<LINK REF="REF-Lucena-2002" TYPE="REFERENCE">Lucena 2002</LINK>). Furthermore, vitamin K is associated with anaphylactoid reactions (<LINK REF="REF-Pereira-1998" TYPE="REFERENCE">Pereira 1998</LINK>; <LINK REF="REF-Fiore-2001" TYPE="REFERENCE">Fiore 2001</LINK>).</P>
<P>We identified no systematic reviews or meta-analyses on vitamin K administration to people with upper gastrointestinal bleeding, apart from our own Cochrane Hepato-Biliary systematic reviews (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2005" TYPE="REFERENCE">Martí-Carvajal 2005</LINK>; <LINK REF="REF-Marti_x002d_Carvajal-2008" TYPE="REFERENCE">Marti-Carvajal 2008</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2012" TYPE="REFERENCE">Martí-Carvajal 2012</LINK>). The present review presents an update of the most recent review published in 2012 (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2012" TYPE="REFERENCE">Martí-Carvajal 2012</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-06-08 13:47:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of vitamin K for people with acute or chronic liver disease and upper gastrointestinal bleeding.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-06-08 13:48:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to include randomised clinical trials (parallel group or cross-over trials) irrespective of publication status (trials could be unpublished or published as an article, an abstract, or a letter), language, and blinding. For cross-over trials, we planned to include only data from the first intervention period.</P>
<P>We intended to include quasi-randomised studies, prospective observational studies, and observational studies with a historical control group in order to assess data on harms.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>People with liver disease and upper gastrointestinal bleeding, irrespective of aetiology.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Vitamin K at any dose, route of administration, and duration of treatment versus placebo or no intervention. Since upper gastrointestinal bleeding in people with liver disease requires different medical and endoscopic treatments (i.e., primary intervention), vitamin K is considered a supplementary intervention. Thus, for the purpose of the review, eligible randomised clinical trials had to compare the same primary interventions with and without vitamin K supplementation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Mortality.</LI>
<LI>Early re-bleeding.</LI>
<LI>Serious adverse events. We used the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>), that is, any untoward medical occurrence that resulted in death, was life threatening, required hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability or incapacity, or was a congenital anomaly or birth defect. We considered all other adverse events as non-serious.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-06-08 13:48:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Quality of life.</LI>
<LI>Non-serious adverse events.</LI>
<LI>Number of participants transfused.</LI>
<LI>Number of blood transfusions.</LI>
<LI>Coagulation factors II, VII, and X.</LI>
<LI>Length of hospital stay.</LI>
<LI>Length of intensive care unit stay.</LI>
</UL>
<P>We planned to report the first seven of the above primary and secondary outcomes in the 'Summary of findings' table.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-06-08 13:48:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched The Cochrane Hepato-Biliary Controlled Trials Register (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid SP), EMBASE (Ovid SP), Science Citation Index EXPANDED, and LILACS (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>) to February 2015. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the search strategies with the time spans of the searches.</P>
<P>We looked through the reference lists of the retrieved publications and review articles.</P>
<P>We also searched the following trial databases for ongoing and unpublished trials:</P>
<UL>
<LI>World Health Organization Clinical Trials Search Portal (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>);</LI>
<LI>metaRegister of controlled trials (<A HREF="http://www.controlled-trials.com/mrct/search.html">www.controlled-trials.com/mrct/search.html</A>).</LI>
</UL>
<P>In future updates, we will also search for study reports at regulatory agencies (US Food and Drug Administration and European Medicines Agency) and trials at <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-06-08 13:48:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to summarise data using standard Cochrane methodology (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<STUDY_SELECTION MODIFIED="2015-06-08 13:48:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>AMC and IS screened the search results for potentially relevant trials and independently assessed them for inclusion or exclusion using a pre-designed eligibility form based on the inclusion criteria. We resolved disagreements through discussion until consensus was reached.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-06-08 13:48:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Due to the lack of randomised clinical trials, we could not follow what is described below. However, if we identify trials in the future, we will follow our protocol as described (<LINK REF="REF-Marti_x002d_Carvajal-2004" TYPE="REFERENCE">Marti-Carvajal 2004</LINK>). We will use a form to extract data from each relevant trial (<LINK REF="REF-Zavala-2006" TYPE="REFERENCE">Zavala 2006</LINK>). Both review authors will independently extract data from the papers and will contact the authors if data are missing. AMC will enter the data into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and IS will check the data. We will extract information on study design and participant characteristics (age, sex, and disease severity as measured by the Child-Pugh score).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-06-08 13:48:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>If we identify randomised clinical trials fulfilling the inclusion criteria of our review, we will independently assess the risk of bias of each included trial according to the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>), The Cochrane Hepato-Biliary Module (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>), and methodological studies (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <A HREF="https://archie.cochrane.org/sections/documents/view?document=52062668095218049629120314134430&amp;format=REVMAN#REF-Lundh-2012">Lundh 2012</A>; <LINK REF="REF-Savovi_x0107_-2012a" TYPE="REFERENCE">Savovi&#263; 2012a</LINK>; <LINK REF="REF-Savovi_x0107_-2012b" TYPE="REFERENCE">Savovi&#263; 2012b</LINK>). We will use the following definitions in the assessment of risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent adjudicator.</LI>
<LI>Unclear risk of bias: the trial was described as randomised, but the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not, or may not have been, random. Quasi-randomised studies, those using dates, names, or admittance numbers in order to allocate participants, were inadequate and were excluded for the assessment of benefits but included for assessing harms.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: allocation was controlled by a central and independent randomisation unit, sequentially numbered, opaque and sealed envelopes or similar, so that intervention allocations could not have been foreseen in advance of, or during, enrolment.</LI>
<LI>Unclear risk of bias: the trial was described as randomised, but the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was known to the investigators who assigned participants, or the study was quasi-randomised.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<UL>
<LI>Low risk of bias: it was mentioned that both participants and personnel providing the interventions were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial.</LI>
<LI>Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding was not described, so that knowledge of allocation was possible during the trial.</LI>
<LI>High risk of bias: the trial was not blinded, so that the allocation was known during the trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinded outcome assessment</HEADING>
<UL>
<LI>Low risk of bias: outcome assessment was carried out blinded for all relevant outcomes, and the method of blinding was described, so that knowledge of allocation was prevented.</LI>
<LI>Unclear risk of bias: blinding of outcome assessment was not described, or the outcome assessment was described as blinded, but the method of blinding was not described, so that knowledge of allocation was possible.</LI>
<LI>High risk of bias: outcome assessment was not blinded, so that the allocation was known to outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias: the trial reported the following pre-defined outcomes: mortality, early re-bleeding, and serious adverse events. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g., <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), the outcomes sought should be those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes were not considered to be reliable.</LI>
<LI>Unclear risk of bias: not all pre-defined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk of bias: one or more pre-defined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conductance, or results of the trial.</LI>
<LI>Unclear risk of bias: the trial may or may not be free of for-profit bias as no information on clinical trial support or sponsorship was provided.</LI>
<LI>High risk of bias: the trial was sponsored by industry or received other type of for-profit support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other bias domains that could put it at risk of bias.</LI>
<LI>Unclear risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
<P>We will judge trials at low risk of bias if assessed with low risk of bias in all above domains. We will judge trials at high risk of bias if assessed with unclear risk of bias or high risk of bias in one or more of the above domains.</P>
<P>We will generate a 'Risk of bias' graph and a 'Risk of bias' summary to show a summary of this assessment.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-06-08 13:48:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>For binary outcomes, such as mortality, early re-bleeding and safety, we planned to calculate the risk ratio (RR) with 95% confidence interval (CI). For continuous outcomes, such as number of people transfused and number of blood transfusions, we planned to calculate the mean difference (MD) with 95% CI.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2015-06-08 13:48:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In the case of missing data on participants or missing statistics (such as standard deviations), we intended to contact the trial authors. If unsuccessful, we planned to base our main analysis on participants who had completed the trial, but we planned to perform sensitivity analysis for worse-case and best-case scenarios according to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Section 16.1 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-06-08 13:48:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to quantify the impact of statistical heterogeneity using the I<SUP>2</SUP> statistic, which describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If the identified trials were comparable enough, we intended to summarise their findings using a random-effects model. In the case of substantial heterogeneity (I<SUP>2</SUP> &gt; 50%), we planned to do further research to identify possible causes of heterogeneity by exploring the impact of participants' characteristics.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-06-08 13:48:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We intended to assess whether the review was subjected to publication bias by using a funnel plot that is usually used to illustrate variability between trials in a graphical way. We needed at least 10 trials in order to be able to make judgements about asymmetry, and if asymmetry was present, we planned to attempt to explore other causes for it (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-06-08 13:48:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We intended to carry out statistical analysis using Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). If the eligible trials were sufficiently comparable in their clinical characteristics, we planned to summarise their findings using the fixed-effect model and the random-effects model according to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Section 9.4 (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). In the case of statistically significant differences between the two models, we intended to report both. Otherwise, we planned to report the results of the model having the most conservative findings (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>A meta-analysis of cumulative data may run the risk of random errors ('play of chance') due to sparse data and repetitive analyses of the same data (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>; 
<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). In order to assess the risks of random errors in cumulative meta-analyses, we planned to conduct diversity-adjusted trial sequential analyses (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>) based on a required information size calculated from the proportion of people with the outcome in the control group; an a priori set relative risk reduction of 20%, an alpha of 5%, a beta of 20%, and the diversity in the meta-analysis (<LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>). We planned to conduct sensitivity analyses of the trial sequential analysis to estimate the potential need for further trials.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-06-08 13:48:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We anticipated clinical heterogeneity in the effects of the intervention, and we planned to conduct the following subgroup analyses when data become available:</P>
<UL>
<LI>trials with low risk of bias (or with lower risk of bias) compared to trials with high risk of bias;</LI>
<LI>participants with cirrhosis compared to participants without cirrhosis;</LI>
<LI>Child-Pugh classification A compared to classification B and compared to classification C.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-06-08 13:48:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to conduct sensitivity analyses including only randomised trials with low risk of bias, and perform best-case and worst-case scenario analyses if there are missing participants.</P>
<P>We intended to seek data on the number of participants randomised to the intervention and control groups, irrespective of compliance and whether or not the participant was later thought to be ineligible or was otherwise excluded from the treatment group or follow-up. If we were unable to do so, we planned to record whether the results of each trial were based on an intention-to-treat analysis or on available participant analysis.</P>
<SUBSECTION>
<HEADING LEVEL="4">'Summary of findings' tables</HEADING>
<P>We intended to use the principles of the GRADE system (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>) in order to assess the quality of the body of evidence associated with specific outcomes (mortality, failure to control bleeding, number of participants receiving a blood transfusion, number of blood transfusions, and adverse events) in our review and construct a 'Summary of findings' table using the GRADEPro software (<A HREF="http://ims.cochrane.org/revman/other-resources/gradepro">ims.cochrane.org/revman/other-resources/gradepro</A>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within-study risk of bias, the indirectness of the evidence, heterogeneity of the data, imprecision of effect estimates, and risk of publication bias (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>; <LINK REF="REF-Guyatt-2011h" TYPE="REFERENCE">Guyatt 2011h</LINK>; <LINK REF="REF-Guyatt-2011i" TYPE="REFERENCE">Guyatt 2011i</LINK>; <LINK REF="REF-Guyatt-2013a" TYPE="REFERENCE">Guyatt 2013a</LINK>; <LINK REF="REF-Guyatt-2013b" TYPE="REFERENCE">Guyatt 2013b</LINK>). We planned to assess the imprecision according to <LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-06-08 13:48:57 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2015-06-08 13:48:57 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The initial bibliographic search identified 462 studies. After manually checking the titles and abstracts, we identified one study to be evaluated further. We excluded the study by <LINK REF="STD-Pereira-2005" TYPE="STUDY">Pereira 2005 </LINK>as it assessed the pharmacokinetics of vitamin K in people with liver diseases. We determined that none of the studies attempted to answer the research questions of this systematic review. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-06-08 13:48:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included no studies.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-06-08 13:48:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The searches did not identify any randomised clinical trials eligible for inclusion in this systematic review. We identified no ongoing trials.</P>
<P>We found no quasi-randomised studies, historically controlled studies, or cohort studies that we could use to assess harms from vitamin K.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-06-08 13:49:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2015-06-08 13:49:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We were unable to identify evidence from randomised clinical trials supporting or refuting the use of vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-06-08 13:49:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In one multicentre hospital study on prescribing patterns for prophylaxis and treatment of complications on cirrhosis, Lucena et al. showed that at discharge, vitamin K was utilised in 24% (range 4% to 53%) of the trial participants (<LINK REF="REF-Lucena-2002" TYPE="REFERENCE">Lucena 2002</LINK>). Lucena et al. also observed that there was a wide variability in prescribing practices across centres, and that the use of non-evidence based treatments such as vitamin K was higher than expected (<LINK REF="REF-Lucena-2002" TYPE="REFERENCE">Lucena 2002</LINK>). In contrast to these observed practices, other studies have shown that there is a risk of anaphylactoid reactions associated with the use of vitamin K (<LINK REF="REF-Pereira-1998" TYPE="REFERENCE">Pereira 1998</LINK>; <LINK REF="REF-ADRAC-2000" TYPE="REFERENCE">ADRAC 2000</LINK>; <LINK REF="REF-Fiore-2001" TYPE="REFERENCE">Fiore 2001</LINK>).</P>
<P>It is widely known that clinicians make practical decisions, often on the basis of inadequate information. Decisions on treatment should be taken based on the results of randomised clinical trials (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>; <LINK REF="REF-Chalmers-2004" TYPE="REFERENCE">Chalmers 2004</LINK>).</P>
<P>The basis for the rational use of vitamin K in people with liver disease with upper gastrointestinal bleeding remains unknown. Randomised clinical trials to answer the research question of this systematic review have not yet been carried out. It is possible that some studies have been carried out, but due to their negative results, they remained unpublished (<LINK REF="REF-Easterbrook-1991" TYPE="REFERENCE">Easterbrook 1991</LINK>; <LINK REF="REF-Gluud-1998" TYPE="REFERENCE">Gluud 1998</LINK>). This causes publication bias, reducing the possibilities to develop valid systematic reviews in certain areas. The existence of high-quality data sufficient to make strong recommendations for an intervention varies considerably across specialities (<LINK REF="REF-Diringer-2003" TYPE="REFERENCE">Diringer 2003</LINK>). This is influenced by a number of factors, from the prevalence of the conditions to the resources available to do research. Keeping clinical uncertainty does not benefit people and may increase health-service costs (<LINK REF="REF-Alderson-2000" TYPE="REFERENCE">Alderson 2000</LINK>). However, admitting clinical uncertainty helps clarify treatment options and encourages further research (<LINK REF="REF-Alderson-2000" TYPE="REFERENCE">Alderson 2000</LINK>; <LINK REF="REF-Diringer-2003" TYPE="REFERENCE">Diringer 2003</LINK>). The paucity of data on vitamin K for people with upper gastrointestinal bleeding in liver disease should stimulate the development of well-planned randomised clinical trials to try to give a response to this widespread practice for upper gastrointestinal bleeding in people with liver disease.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-06-08 13:49:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We were unable to identify evidence from randomised clinical trials supporting the use of vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-06-08 13:49:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In the process of performing this systematic review, we also planned to look for 'significance-chasing biases' (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>), which include, among others, publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias. Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, this Cochrane review contains no trials and as such, we did not evaluate risk of bias. Trials with 'negative' results may have remained unpublished as suppression of information on specific outcomes may have occurred (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). We were unable to identify evidence from randomised clinical trials supporting the use of vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-06-08 13:49:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We were unable to identify evidence from randomised clinical trials supporting or refuting the use of vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-06-08 13:49:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2015-06-08 13:49:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no randomised clinical trials of vitamin K for upper gastrointestinal bleeding for inclusion in this review. Therefore, it was not possible to determine whether vitamin K is beneficial or harmful for upper gastrointestinal bleeding in people with liver diseases. Accordingly, we cannot recommend or refute vitamin K for upper gastrointestinal bleeding in people with acute and chronic liver disease.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-06-08 13:49:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This systematic review has identified the need for well-designed, adequately powered randomised clinical trials to assess the benefits and harms of vitamin K as a way of improving the survival and decreasing mortality from upper gastrointestinal bleeding in people with liver diseases. Potential trials should be planned according to SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement (<LINK REF="REF-Chan-2013a" TYPE="REFERENCE">Chan 2013a</LINK>; <LINK REF="REF-Chan-2013b" TYPE="REFERENCE">Chan 2013b</LINK>). The trials should be reported according to the CONSORT (CONsolidated Standards Of Reporting Trials) statement (<LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>), which helps in improving the quality of reporting of benefits and harms in clinical research (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>; <LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>). Trials should include participant-centred outcomes such as mortality, re-bleeding, and serious and non-serious adverse events as recommended by the Patient-Centered Outcomes Research Institute (P-CORI) statement (<LINK REF="REF-Selby-2013" TYPE="REFERENCE">Selby 2013</LINK>; <LINK REF="REF-Frank-2014" TYPE="REFERENCE">Frank 2014</LINK>; <LINK REF="REF-Selby-2014" TYPE="REFERENCE">Selby 2014</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-06-08 13:49:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We wish to thank Sarah Louise Klingenberg of The Cochrane Hepato-Biliary for conducting the searches and The Cochrane Hepato-Biliary Editorial Team staff for guidance.<BR/>Contact editors: Brian Davidson, UK; Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-08-13 17:08:07 +0200" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-06-08 14:10:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>AMC took the lead on writing up the protocol based on the draft versions, with comments from IS (<LINK REF="REF-Marti_x002d_Carvajal-2004" TYPE="REFERENCE">Marti-Carvajal 2004</LINK>).</P>
<P>Further contribution to the review:</P>
<UL>
<LI>searching: The Cochrane Hepato-Biliary Controlled Trials Register;</LI>
<LI>selection of trials for inclusion: AMC, IS;</LI>
<LI>methodological assessment and extraction of data: AMC, IS;</LI>
<LI>data entry and management: AMC;</LI>
<LI>data analysis: AMC and IS;</LI>
<LI>preparation of the review: AMC, IS.</LI>
</UL>
<P>AMC is guarantor for the review.<BR/>
<BR/>Both authors approved the final review manuscript for publication.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-06-08 13:50:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>We re-arranged the outcomes in terms of what the most relevant outcomes are for the people with liver disease.</LI>
<LI>We planned 'Summary of findings' tables and the outcomes reported within them and will apply these when we identify trials for inclusion.</LI>
<LI>We planned trial sequential analysis and will apply this when we identify trials for inclusion.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-06-08 14:09:22 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This review will not be updated until relevant for the review randomised clinical trials are published.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-06-08 13:54:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2015-03-17 15:28:31 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2015-03-17 15:28:31 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Pereira-2005" MODIFIED="2015-03-17 15:28:31 +0100" MODIFIED_BY="[Empty name]" NAME="Pereira 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-03-17 15:28:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R</AU>
<TI>Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease</TI>
<SO>Journal of Hepatology</SO>
<YR>2005</YR>
<VL>42</VL>
<NO>3</NO>
<PG>365-70</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:28:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-06-19 04:07:50 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-06-08 13:54:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2015-06-08 13:54:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-ADRAC-2000" MODIFIED="2015-06-08 13:51:30 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="ADRAC 2000" TYPE="JOURNAL_ARTICLE">
<AU>Adverse Drug Reactions Advisory Committee (ADRAC)</AU>
<TI>Take care with vitamin K</TI>
<SO>Australian Adverse Drug Reactions Bulletin</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>1</NO>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Afessa-2000" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Afessa 2000" TYPE="JOURNAL_ARTICLE">
<AU>Afessa B, Kubilis PS</AU>
<TI>Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<PG>484-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2000" MODIFIED="2012-07-04 13:10:13 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Alderson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Alderson P, Roberts I</AU>
<TI>Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury research</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2000</YR>
<VL>320</VL>
<PG>376-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2012-07-04 13:10:24 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Alderson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alderson P</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>476-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amitrano-2002" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Amitrano 2002" TYPE="JOURNAL_ARTICLE">
<AU>Amitrano L, Guardascione MA, Brancaccio V, Balzano A</AU>
<TI>Coagulation disorders in liver disease</TI>
<SO>Seminars in Liver Disease</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>83-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2015-05-18 17:16:01 +0200" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS MODIFIED="2015-05-18 17:16:01 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Blonski-2007" MODIFIED="2012-07-04 09:18:29 +0200" MODIFIED_BY="[Empty name]" NAME="Blonski 2007" TYPE="OTHER">
<AU>Blonski W, Siropaides T, Reddy KR</AU>
<TI>Coagulopathy in liver disease</TI>
<SO>Current Treatment Options in Gastroenterology</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>6</NO>
<PG>464-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2015-03-17 15:23:18 +0100" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:23:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2015-06-08 13:51:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2015-05-18 17:16:15 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-2004" MODIFIED="2012-07-04 08:30:53 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Chalmers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I</AU>
<TI>Well informed uncertainties about the effects of treatments. How clinicians and patients respond?</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>475-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2013a" MODIFIED="2015-03-17 14:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al</AU>
<TI>SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2013</YR>
<VL>346</VL>
<PG>e7586</PG>
<IDENTIFIERS MODIFIED="2015-03-17 14:12:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2013b" MODIFIED="2015-03-17 14:12:15 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al</AU>
<TI>SPIRIT 2013 statement: defining standard protocol items for clinical trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2013</YR>
<VL>158</VL>
<NO>3</NO>
<PG>200-7</PG>
<IDENTIFIERS MODIFIED="2015-03-17 14:12:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Czernichow-2000" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Czernichow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow P, Hochain P, Nousbaum JB, Raymond JM, Rudelli A, Dupas JL, et al</AU>
<TI>Epidemiology and course of acute upper gastro-intestinal haemorrhage in four French geographical areas</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2002" MODIFIED="2012-06-19 05:53:39 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="D'Amico 2002" TYPE="COCHRANE_REVIEW">
<AU>D'Amico G, Pagliaro LLP, Pietrosi GGPI, Tarantino IITA</AU>
<TI>Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-05-21 12:58:57 +0200" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-05-21 12:58:57 +0200" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD002233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dallal-2001" MODIFIED="2012-07-04 13:11:20 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Dallal 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dallal HJ, Palmer KR</AU>
<TI>ABC of the upper gastrointestinal tract: upper gastrointestinal haemorrhage</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2015-06-08 13:51:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-del-Olmo-2000" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="del Olmo 2000" TYPE="JOURNAL_ARTICLE">
<AU>del Olmo JA, Pena A, Serra MA, Wassel AH, Benages A, Rodrigo JM</AU>
<TI>Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diringer-2003" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Diringer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Diringer MN</AU>
<TI>Evidence-based medicine: what do you do when there's no evidence?</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>2</NO>
<PG>659-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Easterbrook-1991" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Easterbrook 1991" TYPE="JOURNAL_ARTICLE">
<AU>Easterbrook PJ, Berlin J, Gopalan R, Matthews DR</AU>
<TI>Publication bias in clinical research</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiore-2001" MODIFIED="2012-07-04 13:12:17 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Fiore 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fiore LD, Scola MA, Cantillon CE, Brophy MT</AU>
<TI>Anaphylactoid reactions to vitamin K</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2001</YR>
<VL>11</VL>
<PG>175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frank-2014" MODIFIED="2015-03-17 15:14:11 +0100" MODIFIED_BY="[Empty name]" NAME="Frank 2014" TYPE="JOURNAL_ARTICLE">
<AU>Frank L, Basch E, Selby JV</AU>
<TI>The PCORI perspective on patient-centered outcomes research</TI>
<SO>JAMA</SO>
<YR>2014</YR>
<VL>312</VL>
<NO>15</NO>
<PG>1513-4</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:14:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-1998" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Gluud 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gluud C</AU>
<TI>"Negative trials" are positive!</TI>
<SO>Journal of Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>4</NO>
<PG>731-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2015" MODIFIED="2015-06-08 13:52:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Gluud 2015" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2015, Issue 1. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2003" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Green 2003" TYPE="JOURNAL_ARTICLE">
<AU>Green BT, Rockey DC</AU>
<TI>Acute gastrointestinal bleeding</TI>
<SO>Seminars in Gastrointestinal Disease</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>44-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2015-06-07 16:06:08 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A</AU>
<TI>GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>380-2</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2015-06-08 13:52:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2015-06-07 16:06:01 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2015-06-07 16:05:58 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2015-06-07 16:05:55 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence - publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2015-06-07 16:05:50 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines: 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:23:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2015-06-07 16:05:45 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:22:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011h" MODIFIED="2015-06-07 16:05:40 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011h" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011i" MODIFIED="2015-06-07 16:05:35 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011i" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:17:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013a" MODIFIED="2015-06-08 13:52:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2013a" TYPE="OTHER">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al</AU>
<TI>GRADE guidelines 12. Preparing summary of findings tables - binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013b" MODIFIED="2015-06-07 16:06:25 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2013b" TYPE="OTHER">
<AU>Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines 11 - making an overall rating of confidence in effect estimates for a single outcome and for all outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>151-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-07-04 13:09:16 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2015-06-08 13:53:03 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2015-06-08 13:53:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2015-03-26 14:07:24 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>Pennsylvania</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>10</NO>
<PG>781-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2012-07-04 09:48:17 +0200" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>The art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannou-1999" MODIFIED="2012-06-19 05:53:50 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Ioannou 1999" TYPE="COCHRANE_REVIEW">
<AU>Ioannou G, Doust J, Rockey DC</AU>
<TI>Terlipressin for acute esophageal variceal hemorrhage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-05-21 12:59:16 +0200" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-05-21 12:59:16 +0200" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD002147"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2015-05-18 17:09:16 +0200" MODIFIED_BY="[Empty name]" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J</AU>
<TI>The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>34</PG>
<IDENTIFIERS MODIFIED="2015-05-18 17:09:16 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2011" MODIFIED="2012-06-19 04:32:47 +0200" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kavanagh C, Shaw S, Webster CR</AU>
<TI>Coagulation in hepatobiliary disease</TI>
<SO>Journal of Veterinary Emergency and Critical Care</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>6</NO>
<PG>589-604</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22316251"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2012-07-03 13:50:30 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Longstreth-1998" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Longstreth 1998" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth GF, Feitelberg SP</AU>
<TI>Successful outpatient management of acute upper gastrointestinal hemorrhage: use of practice guidelines in a large patient series</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucena-2002" MODIFIED="2012-07-04 09:50:32 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Lucena 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sánchez de la Cuesta F; the Spanish Collaborative Study Group on Therapeutic Management in Liver Disease</AU>
<TI>Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2002</YR>
<VL>58</VL>
<PG>435-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2012-07-03 13:50:30 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2015-05-18 17:16:50 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c869</PG>
<IDENTIFIERS MODIFIED="2015-05-18 17:16:50 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-1998" MODIFIED="2015-03-17 15:16:52 +0100" MODIFIED_BY="[Empty name]" NAME="Pereira 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pereira SP, Williams R</AU>
<TI>Adverse events associated with vitamin K1: results of a worldwide postmarketing surveillance programme</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>3</NO>
<PG>173-82</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:16:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Pluta-2010" MODIFIED="2012-06-19 04:32:11 +0200" MODIFIED_BY="[Empty name]" NAME="Pluta 2010" TYPE="JOURNAL_ARTICLE">
<AU>Pluta A, Gutkowski K, Hartleb M</AU>
<TI>Coagulopathy in liver diseases</TI>
<SO>Advances in Medical Sciences</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>1</NO>
<PG>16-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20513645"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Protell-1981" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Protell 1981" TYPE="JOURNAL_ARTICLE">
<AU>Protell RL, Silverstein FE, Gilbert DA, Feld AD</AU>
<TI>Severe upper gastrointestinal bleeding. Part I: causes, pathogenesis and methods of diagnosis</TI>
<SO>Clinics in Gastroenterology</SO>
<YR>1981</YR>
<VL>10</VL>
<PG>17-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-06-08 13:53:46 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2012-07-03 14:05:25 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012a" MODIFIED="2015-06-07 16:08:53 +0200" MODIFIED_BY="Anne Lawson" NAME="Savovi&#263; 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012b" MODIFIED="2015-06-07 16:08:50 +0200" MODIFIED_BY="Anne Lawson" NAME="Savovi&#263; 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2012-07-03 13:50:30 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selby-2013" MODIFIED="2015-03-17 15:14:35 +0100" MODIFIED_BY="[Empty name]" NAME="Selby 2013" TYPE="JOURNAL_ARTICLE">
<AU>Selby JV</AU>
<TI>The patient-centered outcomes research institute: a 2013 agenda for "research done differently"</TI>
<SO>Population Health Management</SO>
<YR>2013</YR>
<VL>16</VL>
<NO>2</NO>
<PG>69-70</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:14:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Selby-2014" MODIFIED="2015-03-17 15:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="Selby 2014" TYPE="OTHER">
<AU>Selby JV</AU>
<TI>Patient-Centered Outcomes Research Institute seeks to find out what works best by involving 'end-users' from the beginning</TI>
<SO>Journal of Comparative Effectiveness Research</SO>
<YR>2014</YR>
<VL>3</VL>
<NO>2</NO>
<PG>125-9</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:15:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sostres-2011" MODIFIED="2015-03-17 15:15:32 +0100" MODIFIED_BY="[Empty name]" NAME="Sostres 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sostres C, Lanas A</AU>
<TI>Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality</TI>
<SO>Gastrointestinal Endoscopy Clinics of North America</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>4</NO>
<PG>567-81</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:15:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-03-17 15:24:04 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:24:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2015-06-07 15:39:25 +0200" MODIFIED_BY="Anne Lawson" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:16:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2015-03-17 15:16:31 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:16:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2015-06-08 13:54:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for trial sequential analysis (TSA), 2011</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>(accessed 30 April 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tripodi-2005" MODIFIED="2008-05-21 12:57:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Tripodi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al</AU>
<TI>Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests</TI>
<SO>Hepatology</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>553-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tripodi-2011" MODIFIED="2015-03-26 14:10:14 +0100" MODIFIED_BY="[Empty name]" NAME="Tripodi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tripodi A, Mannucci PM</AU>
<TI>The coagulopathy of chronic liver disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>365</VL>
<NO>2</NO>
<PG>147-56</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:15:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2015-03-26 13:59:30 +0100" MODIFIED_BY="[Empty name]" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Leerdam-2008" MODIFIED="2015-03-17 15:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="van Leerdam 2008" TYPE="JOURNAL_ARTICLE">
<AU>van Leerdam ME</AU>
<TI>Epidemiology of acute upper gastrointestinal bleeding</TI>
<SO>Best Practice &amp; Research. Clinical Gastroenterology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>2</NO>
<PG>209-24</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:16:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2015-03-17 15:15:53 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:15:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2012-07-13 12:07:13 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2012-07-13 12:04:21 +0200" MODIFIED_BY="Arturo J Marti-Carvajal">
<IDENTIFIER TYPE="PUBMED" VALUE="20042080"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wicklund-2011" MODIFIED="2015-03-17 15:16:02 +0100" MODIFIED_BY="[Empty name]" NAME="Wicklund 2011" TYPE="JOURNAL_ARTICLE">
<AU>Wicklund BM</AU>
<TI>Bleeding and clotting disorders in pediatric liver disease</TI>
<SO>Hematology</SO>
<YR>2011</YR>
<VL>2011</VL>
<PG>170-7</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:16:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2015-03-17 15:16:13 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2015-03-17 15:16:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zaltman-2002" MODIFIED="2012-07-04 10:30:29 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Zaltman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Zaltman C, Souza HS, Castro ME, Sobral Mde F, Dias PC, Lemos V Jr</AU>
<TI>Upper gastrointestinal bleeding in a Brazilian hospital: a retrospective study of endoscopic records</TI>
<SO>Arquivos de Gastroenterologia</SO>
<YR>2002</YR>
<VL>39</VL>
<PG>74-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2006" MODIFIED="2015-06-08 13:54:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Zavala 2006" TYPE="COMPUTER_PROGRAM">
<TI>Zavala D, Martí A, Peña-Martí G, Comunián G. Sheet to enter data for performing a Cochrane review</TI>
<YR>2006</YR>
<PB>Venezuela: Universidad de Carabobo</PB>
<CY>Valencia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhao-2008" MODIFIED="2015-06-08 13:54:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Zhao 2008" TYPE="OTHER">
<AU>Zhao Y, Encinosa W</AU>
<TI>Hospitalizations for gastrointestinal bleeding in 1998 and 2006 statistical brief #65, 2008</TI>
<SO>www.ncbi.nlm.nih.gov/books/NBK54562/</SO>
<YR>(accessed 26 March 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-03-26 14:34:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Marti_x002d_Carvajal-2004" MODIFIED="2015-03-26 14:32:54 +0100" MODIFIED_BY="[Empty name]" NAME="Marti-Carvajal 2004" TYPE="COCHRANE_PROTOCOL">
<AU>Martí-Carvajal AJ, Martí-Peña A</AU>
<TI>Vitamin K for upper gastrointestinal bleeding in patients with liver diseases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-03-26 14:32:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-26 14:32:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004792"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marti_x002d_Carvajal-2008" MODIFIED="2015-03-26 14:34:07 +0100" MODIFIED_BY="[Empty name]" NAME="Marti-Carvajal 2008" TYPE="COCHRANE_REVIEW">
<AU>Marti-Carvajal AJ, Cortes-Jofre M, Marti-Pena AJ</AU>
<TI>Vitamin K for upper gastrointestinal bleeding in patients with liver diseases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-03-26 14:33:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-26 14:33:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004792.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2005" MODIFIED="2015-03-26 14:33:19 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2005" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Martí-Peña AJ</AU>
<TI>Vitamin K for upper gastrointestinal bleeding in patients with liver diseases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-06-19 04:21:12 +0200" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2012-06-19 04:21:12 +0200" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD004792.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2012" MODIFIED="2015-03-26 14:34:46 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2012" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Solà I</AU>
<TI>Vitamin K for upper gastrointestinal bleeding in patients with acute or chronic liver diseases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2015-03-17 14:02:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-17 14:02:41 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004792.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-03-17 15:13:33 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-06-08 13:50:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-06-08 13:50:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-06-08 13:50:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pereira-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-08 13:50:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>A pharmacokinetics randomised trial on vitamin K in people with liver diseases.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-06-19 04:07:50 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-21 12:57:35 +0200" MODIFIED_BY="dimitrinka nikolova"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2015-06-08 13:55:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-06-08 13:55:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram (25 February 2015).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAKWCAYAAABj+x9xAAA990lEQVR42u2df4RW29uHD0mSJJKM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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-06-08 14:08:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2015-06-08 14:08:17 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2012-08-13 17:05:12 +0200" MODIFIED_BY="dimitrinka nikolova">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-08 14:08:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="3" ROWS="9">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Name of database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span of search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(vitamin k OR phylloquinon* OR menaquinon* OR menadion*) AND liver disease*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2 of 12, 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Vitamin K] explode all trees</P>
<P>#2 (vitamin* next K) or phylloquinon* or menaquinon* or menadion*</P>
<P>#3 #1 or #2</P>
<P>#4 MeSH descriptor: [Gastrointestinal Hemorrhage] explode all trees</P>
<P>#5 bleed* or h*emorrhage*</P>
<P>#6 #4 or #5</P>
<P>#7 MeSH descriptor: [Liver Diseases] explode all trees</P>
<P>#8 liver disease*</P>
<P>#9 #7 or #8</P>
<P>#10 #3 and #6 and #9</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Vitamin K/</P>
<P>2. ('vitamin K' or phylloquinon* or menaquinon* or menadion*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>3. 1 or 2</P>
<P>4. exp Gastrointestinal Hemorrhage/</P>
<P>5. (bleed* or h*emorrhage*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>6. 4 or 5</P>
<P>7. exp Liver Diseases/</P>
<P>8. liver disease*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>9. 7 or 8</P>
<P>10. 3 and 6 and 9</P>
<P>11. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>12. 10 and 11</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp vitamin K group/</P>
<P>2. ('vitamin K' or phylloquinon* or menaquinon* or menadion*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>3. 1 or 2</P>
<P>4. exp gastrointestinal hemorrhage/</P>
<P>5. (bleed* or h*emorrhage*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>6. 4 or 5</P>
<P>7. exp liver disease/</P>
<P>8. liver disease*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>9. 7 or 8</P>
<P>10. 3 and 6 and 9</P>
<P>11. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>12. 10 and 11</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index EXPANDED</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#6 #5 AND #4</P>
<P>#5 TS=(random* or blind* or placebo* or meta-analys*)</P>
<P>#4 #3 AND #2 AND #1</P>
<P>#3 TS="liver disease*"</P>
<P>#2 TS=(bleed* or h*emorrhage*)</P>
<P>#1 TS=("vitamin K" or phylloquinon* or menaquinon* or menadion*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1982 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1) Vitamin K<BR/>(2) liver diseases<BR/>(3) 1+2<BR/>(4) ((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((CT ANIMALS OR MH ANIMALS OR CT RABBITS OR CT MICE OR MH RATS OR MH PRIMATES OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS))<BR/>(5) 3 + 4</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>World Health Organization Clinical Trials Search Portal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25 February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Upper gastrointestinal bleeding AND liver disease AND vitamin K</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>metaRegister of Controlled Trials (mRCT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25 February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>liver disease AND vitamin K</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 full-text article assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;462 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;462 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;429 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;33 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;461 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 study excluded (pharmacokinetics study)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="119"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>